Biotech Values

[n4807g]

Juno, Kite Valuations at Risk From Simpler T-Cell Cancer Therapy
http://www.thestreet.com/story/13436157/1/juno-kite-valuations-at-risk-from-simpler-t-cell-cancer-therapy.html?puc=yahoo&cm_ven=YAHOO


_____________________________________________________________________________________________________________________________________

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

Results Eight of 20 treated patients obtained remission, which included six complete remissions (CRs) and two partial remissions. The response rate was highest for acute lymphoblastic leukemia, with four of five patients obtaining minimal residual disease–negative CR. Responses also occurred in chronic lymphocytic leukemia and lymphoma. The longest ongoing CR was more than 30 months in a patient with chronic lymphocytic leukemia. New-onset acute graft-versus-host disease after CAR T-cell infusion developed in none of the patients.

http://jco.ascopubs.org/content/early/2016/01/21/JCO.2015.64.5929?cmpid=jco_pap_25Jan2016